| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | AF643-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | 643-VM-200 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-47491SS | |||
| Azide and BSA Free | NBP2-81005 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | AF809-SP | |||
![N/A VCAM-1/CD106 [HRP]](http://images.novusbio.com/fullsize2/DATA_VCAM1_DVC00_ELISA_869.jpg "N/A VCAM-1/CD106 [HRP]")
![N/A VCAM-1/CD106 [HRP]](http://images.novusbio.com/fullsize2/VCAM-1_DVC00_ELISA_206.jpg)
![Western Blot: VCAM-1/CD106 Antibody (6G9) [NBP1-47491] - Using VCAM1 mouse mAb against (1) HUVEC and (2) EC cell lysate.](http://images.novusbio.com/fullsize/VCAM-1-CD106-Antibody-6G9-Western-Blot-NBP1-47491-img0006.jpg "Western Blot: VCAM-1/CD106 Antibody (6G9) [NBP1-47491] - Using VCAM1 mouse mAb against (1) HUVEC and (2) EC cell lysate.")
![Immunohistochemistry: VCAM-1/CD106 Antibody (6G9) [NBP1-47491] - Photomicrographs of two separate gut sections from a patient with EHEC colitis. Panels (C) and (D) are stained to show VCAM-1/CD106 expression in endothelium, indicating inflammatory activation (40x magnification). Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0055278), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/VCAM-1-CD106-Antibody-6G9-Immunohistochemistry-NBP1-47491-img0010.jpg)
![Immunohistochemistry-Paraffin: VCAM-1/CD106 Antibody (6G9) [NBP1-47491] - (A) human lung cancer and (B) colon cancer using VCAM1 mouse mAb with DAB staining.](http://images.novusbio.com/fullsize/VCAM-1-CD106-Antibody-6G9-Immunohistochemistry-Paraffin-NBP1-47491-img0004.jpg)
![Immunohistochemistry-Paraffin: VCAM-1/CD106 Antibody (6G9) [NBP1-47491] - Human placenta tissues using VCAM1 mouse mAb.](http://images.novusbio.com/fullsize/VCAM-1-CD106-Antibody-6G9-Immunohistochemistry-Paraffin-NBP1-47491-img0005.jpg)
![Immunohistochemistry: VCAM-1/CD106 Antibody (6G9) [NBP1-47491] - Breast carcinoma, cytoplasmic staining. IHC image submitted by a verified customer review.](http://images.novusbio.com/fullsize/VCAM-1-CD106-Antibody-6G9-Immunohistochemistry-NBP1-47491-img0007.jpg)
![Immunohistochemistry-Paraffin: VCAM-1/CD106 Antibody (6G9) [NBP1-47491] - FFPE section of human lung cancer. Image at 20X magnification. IHC-P image submitted by a verified customer review.](http://images.novusbio.com/fullsize/VCAM-1-CD106-Antibody-6G9-Immunohistochemistry-Paraffin-NBP1-47491-img0009.jpg)
![Simple Western: VCAM-1/CD106 Antibody (6G9) [NBP1-47491] - Lane view shows a specific band for CD106/VCAM1 in 0.5 mg/mL of HUVEC lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/VCAM-1-CD106-Antibody-6G9-Simple-Western-NBP1-47491-img0008.jpg)
![Immunocytochemistry/ Immunofluorescence: VCAM-1/CD106 Antibody (6G9) - BSA Free [NBP1-47491] - Enhanced expression of endothelial SENP1 & GATA2 correlates w/ graft arteriosclerosis (GA) progression.Similarly sized human coronary arteries w/ GA from chronically rejecting heart allografts or w/out disease from non-transplanted hearts collected & evaluated by histological analysis. (a,b) Dramatically increased expression of endothelial SENP1 detected in the diseased vessel wall. Endothelial SENP1 expression is demonstrated by immunofluorescence analysis of coronary artery cross-sections that stained for SENP1 & the endothelial marker PECAM-1 w/ DAPI labelling of the nuclei. Representative images are shown in (a) w/ quantification data in (b). Bar represents 50 μm. (c) Induction of endothelial adhesion molecules resulted in a similar augmented pattern as endothelial SENP1. Representative images of immunofluorescence staining for VCAM-1 or P-selectin & PECAM-1 in coronary arteries w/ DAPI counterstaining are shown. Bar represents 50 μm. (d,e) Expression of endothelial GATA2 elevated w/ the progression of aggravated rejection. Representative images of the immunofluorescence staining of coronary arteries for GATA2 & PECAM-1 together w/ DAPI nuclear staining are shown in (d) w/ quantification data in (e). Negative SENP1 & GATA2 staining in the isotype or blocking peptide controls are also shown in (a) & (d). Bar represents 50 μm. Data presented in (b,e) are the mean±s.e.m. from five separate clinical specimens per group as indicated. *P<0.05, **P<0.01 & ***P<0.0001; one-way ANOVA followed by Bonferroni test. GA, graft arteriosclerosis; PECAM, platelet/endothelial cell adhesion molecule; SENP, sentrin-specific protease; VCAM, vascular cell adhesion molecule. Image collected & cropped by CiteAb from the following publication (//www.nature.com/articles/ncomms15426), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-47491_mouse-monoclonal-vcam-1-cd106-antibody-6g9-310202416161834.jpg)
![Immunocytochemistry/ Immunofluorescence: VCAM-1/CD106 Antibody (6G9) - BSA Free [NBP1-47491] - Loss of endothelial SENP1 inhibits EC activation.(a) Grafts from WT or SENP1-ecKO mice were harvested 3 days post-transplantation. The induction of endothelial adhesion molecules was demonstrated by immunofluorescence staining of ICAM-1, VCAM-1, or P-selectin & PECAM-1 with DAPI labelling of the nuclei. Bar represents 50 μm. (b–e) Attenuated induction of adhesion molecules in SENP1-ecKO MAECs. Flow cytometry analysis of ICAM-1, VCAM-1 & P-selectin in MAECs isolated from WT or SENP1-ecKO mice after TNF or IL-1 beta treatment. Representative histograms are shown in (b) with the quantification of mean intensity in (c–e). (f–h) Overexpression of the catalytically inactive form of SENP1 (SENP1-Mut) inhibits the induction of adhesion molecules in HUVECs. HUVECs were infected by Ad-SENP1-Mut or vector control (Ad-LacZ) for 24 h, treated with pro-inflammatory cytokines & analysed by flow cytometry in the same way as MAECs. Representative histograms of ICAM-1 & VCAM-1 are shown in (f) with the quantification of mean intensity in (g,h). Data are presented as the mean±s.e.m. from at least three independent experiments. *P<0.05 & **P<0.01; two-way ANOVA followed by Bonferroni post-test. MAEC, mouse aortic endothelial cell. Image collected & cropped by CiteAb from the following publication (//www.nature.com/articles/ncomms15426), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-47491_mouse-monoclonal-vcam-1-cd106-antibody-6g9-31020241616185.jpg)
![N/A VCAM-1/CD106 [HRP]](http://images.novusbio.com/fullsize2/DATA_VCAM1_MVC00_ELISA_1046.jpg "N/A VCAM-1/CD106 [HRP]")
![N/A VCAM-1/CD106 [HRP]](http://images.novusbio.com/fullsize2/DATA_VCAM1_MVC00_ELISA_1047.jpg)
![N/A VCAM-1/CD106 [HRP]](http://images.novusbio.com/fullsize2/VCAM-1_MVC00_ELISA_336.jpg)
![N/A VCAM-1/CD106 [Biotin]](http://images.novusbio.com/fullsize2/DATA_VCAM1_DY809_ELISA_2240.jpg "N/A VCAM-1/CD106 [Biotin]")
![N/A VCAM-1/CD106 [Biotin]](http://images.novusbio.com/fullsize2/DATA_VCAM1_DY643_ELISA_2162.jpg "N/A VCAM-1/CD106 [Biotin]")